Title: LegoChem attracts venture capital funds
Publication: E-today / In-Hyo Kang
Date: 6 Nov 2014
Summary
● The
investment magnate Min-Joo Lee, President of Atinum Partners, is known to
invest in LegoChem Biosciences again.
● InterVest
and Korea Investment Partners, which also have paid particular attention to
biotech/pharmaceutical industry, are investing in LegoChem along with Atinum.
● According
to a source, Mr. Lee is seeing that LegoChem’s lucrative oncology pipeline,
particularly Antibody-Drug Conjugates (ADCs) proprietary technology will offer
a great growth potential.
To view the full article (in Korean), click here ▶
About LegoChem
Biosciences
LegoChem Biosciences,
Inc. (LCB) is a research-based biotechnology company dedicated to discovering,
developing, and commercializing innovative medicines by leveraging our
chemistry expertise to make conventional biologics targeted and more potent for
the benefit of patients with diseases of high unmet medical needs. We are
advancing sustainable pipelines in therapeutic areas in antibiotics,
anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug
conjugate (PDC).
| 
